Inscripta announces strategic acquisition of Solana Biosciences
BOULDER -- Inscripta , a leading gene-editing technology company, today announced the strategic acquisition of Solana Biosciences, a life sciences company founded by Illumina (NASDAQ: ILMN)... Read More
Thursday September 6, 2018 0 comments
Inscripta announces two major milestones
BOULDER -- Inscripta , a gene-editing technology company, announced two significant milestones. First, the USPTO granted Inscripta its first patent covering systems using MAD7, the... Read More
Friday July 13, 2018 0 comments
Inscripta raises $55.5M to advance gene-editing tech
BOULDER -- Inscripta , a leading gene-editing technology company, announced it closed a $55.5 million Series C funding round led by Merieux Developpement and Paladin Capital Group. ... Read More
Wednesday February 28, 2018 0 comments
Muse bio appoints John Stuelpnagel chairman of board of directors
BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering capabilities, announced Dr. John Stuelpnagel , co-founder, first CEO and former COO... Read More
Tuesday May 16, 2017 0 comments
Muse bio secures $23M Series B funding led by Venrock investor group
BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering capabilities, today announced completion of a$23 millionSeries B financing. The... Read More
Tuesday February 28, 2017 0 comments
Muse bio appoints Kevin Ness new company CEO
BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering technologies, announced Dr.Kevin Ness has been appointed CEO and a member of the... Read More
Friday December 9, 2016 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
